Startup profile · funding coverage
Remedy Robotics funding, valuation and investors
Developer of the investigational N1 robot for image-guided, remotely operable endovascular procedures.
Verified company research · funding, investors and latest developments
Keep track of Remedy Robotics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$62M · November 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$62M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Francisco, California, United States
Investors in latest funding
Lead: DCVC
Other: UC Investments , Skip Capital , Hostplus , Build Collective , Blackbird , Divergent Capital , KdT Ventures
Overview
Remedy Robotics develops the N1 image-guided robotic platform intended to let specialist physicians conduct complete minimally invasive catheter procedures at a hospital, from another site, or with future supervised autonomous assistance. Its software uses preoperative imaging, case simulation and 3D-to-2D registration to support catheter navigation.
The company reported first-in-human procedures in Toronto in 2024 and remote human procedures in 2025. The N1 is investigational, not FDA-approved or available for commercial sale; safety, effectiveness, pricing and procurement terms are not established.
Why Remedy Robotics is interesting
Its November 16, 2026 $62M Series B, led by DCVC, is intended to fund a pivotal trial and FDA review rather than scale sales of an approved product. Remote neurovascular procedures have been reported in small first-in-human studies, but no approved commercial device or validated economic outcome has been established.
Product & use cases
Representative clinician workflow (illustrative, not a hands-on test): (1) hospital identifies a patient requiring specialist neurovascular intervention and acquires the necessary imaging; (2) trained physician reviews the images and proposed plan; (3) N1 software analyzes preoperative imaging and offers case simulation and image registration; (4) the physician remotely or locally controls robotic tools through an operator console, with imaging feedback; (5) clinician evaluates the procedural result and provides standard post-procedure monitoring. Remedy's own website describes 2024 first-in-human and 2025 remote demonstrations. Such studies do not prove general clinical safety, commercial readiness or unsupervised autonomy.
- Potential inter-hospital remote thrombectomy for regions without on-site specialists; proposed future use, not currently offered clinical service.
- Physician-operated endovascular catheter procedures with robotic precision in controlled research settings.
- Pre-procedure imaging interpretation and procedural simulation for specialists.
Key facts
- $62M Series B announced Nov 16, 2026, led by DCVC; legal settlement date and valuation undisclosed.
- New investors UC Investments, Skip Capital and Hostplus; returning Build Collective, Blackbird, Divergent Capital and KdT Ventures.
- Company reports relationships with over 100 hospitals, NOT 100 commercial deployments or proven outcomes.
- N1 remains an investigational device; FDA clearance or approval has not been established.
Funding history (newest first)
Series B
2026-11-16 $62M- DCVC (lead)
- UC Investments (participant)
- Skip Capital (participant)
- Hostplus (participant)
- Build Collective (participant)
- Blackbird (participant)
- Divergent Capital (participant)
- KdT Ventures (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Claimed differentiation is end-to-end robotic catheter procedures with teleoperation and machine-learning visualization. The extent of clinical benefit versus standard catheterization and other robotics has not been established by independently verified comparative studies.
Primary comparison is to manual specialist-delivered intervention and existing robot-assisted vascular systems. Key adoption gates: rigorous pivotal trial results, FDA authorization for specific indications, physician training, cath-lab infrastructure, connectivity resiliency, workflow handoff, reimbursement and purchase/service economics. Never label its remote cases proof of better outcomes or its hospital network as paying customers.
-
Conventional manual endovascular thrombectomy incumbent
Existing clinical standard delivered by specialist neurointerventional teams; no robot purchase but requires specialized local staff.
-
Corindus/Siemens Healthineers CorPath adjacent
Established robotic vascular intervention platform; application scope and regulatory indications differ and require careful procedure-level comparison.
-
Microbot Medical LIBERTY adjacent
Robotic endovascular platform with a different technology/indication path; no evidence that users can interchange them directly.
Notable stories
- Issuer announcement, 16 Nov 2026: prnewswire.com (external source)
- Official product and investigational status: remedyrobotics.com (external source)
- Official first-in-human report, Dec 10 2024: remedyrobotics.com (external source)
- Official October 2025 Mission Thrombectomy partnership: remedyrobotics.com (external source)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Remedy Robotics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.